Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.
We present three patients in whom Fluosol-DA 20 percent was administered in the presence of ischemic cerebral vascular disease. While transient improvement observed in two cases may have been related to Fluosol-DA administration it is premature to use these results to comment on the potential protective or therapeutic efficacy of Fluosol-DA in ischemic cerebral vascular disease. One patient progressively deteriorated neurologically during and after the infusion. Our initial impressions are limited to the observations that Fluosol-DA in doses of 20 ml/kg can be administered easily and without major effects on hemodynamic or pulmonary function. One patient had a transient leukopenia.
D000208:Acute Disease; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001802:Blood Substitutes / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D008297:Male; D008875:Middle Aged
D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination